IO Biotech has entered into a collaborative agreement with Merck & Co (NYSE: MRK), known as MSD outside the US and Canada, through a subsidiary, to clinically evaluate IO102 in combination with Keytruda (pembrolizumab) in patients with non-small cell lung cancer, the private Danish company disclosed on Monday.
IO102, IO Biotech's lead candidate, is an IDO-derived immune modulating therapy with dual mode of action killing both cancer and immune-suppressive cells.
The company's other IDO-derived immune modulating therapies have previously shown a favourable safety profile, as well as signs of promising anti-tumour activity in a first-in-man trial of heavily pre-treated patients with NSCLC.
The terms of the collaboration state that IO Biotech will conduct an international Phase 1/2 study to evaluate the combination of IO102 with MSD's anti-PD-1 therapy. The study will involve an open-label, randomised, Phase 1/2 trial investigating the safety and efficacy of IO1012 in combination with pembrolizumab, with or without chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer.
IO Biotech will sponsor the clinical trials, while MSD will provide the trial with Keytruda. The two companies will share the rights to the study results, but IO Biotech will maintain global commercial rights to IO102.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study